HUGHES RAC

Last name: HUGHES RAC

2016 (v1)

Publication

Metadata-only

Nerve conduction velocity in CMT1A: what else can we tell?

Manganelli F Pisciotta C Reilly MM

Background and purpose: Charcot-Marie-Tooth disease (CMT) type 1A is characterized by uniformly reduced nerve conduction velocity (NCV) that is fully penetrant since the first years of life, remains fairly stable through the life and does not correlate with disability whereas compound muscular action potential (CMAP) amplitude does. The aim of...

Uploaded on: April 14, 2023
2006 (v1)

Publication

Metadata-only

A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol

Pareyson D Schenone A Fabrizi GM

No description

Uploaded on: April 14, 2023
2008 (v1)

Publication

Metadata-only

Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.

Hughes RAC Donofrio P Bril V

Short-term studies suggest that intravenous immunoglobulin might reduce disability caused by chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) but long-term effects have not been shown. We aimed to establish whether 10% caprylate-chromatography purified immune globulin intravenous (IGIV-C) has short-term and long-term benefit in...

Uploaded on: April 14, 2023
2011 (v1)

Publication

Metadata-only

Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.

Pareyson D Reilly MM Schenone A

No description

Uploaded on: March 31, 2023

HUGHES RAC

Recent uploads